Clinicians explain zanidatamab’s action and HORIZON-GEA-01
Back
Evolving First-Line Treatment Strategies in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
In this OncLive® Peer Exchange, moderator Zev Wainberg, MD, MSc (David Geffen School of Medicine at UCLA, Santa Monica, CA) is joined by panelists Elena Elimova, MD (Princess Margaret Cancer Centre, Toronto, ON); Manish A. Shah, MD (Weill Cornell Medicine, New York, NY); and Raj Shameem, MD (Orlando Health Cancer Institute, Orlando, FL) for a discussion on evolving first-line treatment strategies in HER2-positive metastatic gastroesophageal adenocarcinoma (GEA). The panel unpacks the phase 3 HERIZON-GEA-01 trial of zanidatamab plus chemotherapy and zanidatamab plus tislelizumab plus chemotherapy versus trastuzumab plus chemotherapy, addressing the biparatopic mechanism of zanidatamab, interpretation of PD-L1 tumor area positivity (TAP) and combined positive score (CPS) data, HER2 heterogeneity and retesting at progression, proactive diarrhea prophylaxis, second-line sequencing with trastuzumab deruxtecan (T-DXd), upcoming trials (ARTEMIDE-Gastric01, DESTINY-Gastric05, HLX22), and patient-facing conversations. Tailored for community and academic oncologists, board-certified oncology pharmacists (BCOPs), and multidisciplinary oncology care teams.
Evolving First-Line Treatment Strategies in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
Episodes
All
All
Experts unpack zanidatamab’s dual HER2 binding, why JACOB nearly succeeds, and what standout gastric and biliary cancer responses mean next.
Zanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.
Experts debate PD‑L1 testing in HER2+ metastatic gastric cancer as new trial data reshapes when to add immunotherapy.
HORIZON GEA 01 shows zanidatamab regimens significantly improve survival in HER2-positive gastric, esophageal, and GEJ cancer, while PD-L1 testing differences raise key questions for treatment choice.
New HER2+ gastric cancer data show triplet immunotherapy boosts survival and durable responses, hinting immune activation beyond HER2 targets.
New trial updates tease stronger survival with zanidatumab combos; two analyses ahead may clarify OS, biomarkers, and tislelizumab’s added value.
Experts weigh using triplet immunotherapy plus chemo for PD‑L1–negative patients, balancing survival gains, side effects, and FDA approval in first-line care.
Clinicians share real-world tips to prevent and manage zanidatamab-related diarrhea, using early loperamide, patient counseling, follow-up calls, and supportive care.
Experts weigh T‑DXd for HER2+ gastric cancer after prior therapy, stressing rebiopsy or ctDNA confirmation and vigilant pneumonitis monitoring.
Experts weigh T‑DXd as second-line HER2+ gastric cancer therapy, stressing rebiopsy/ctDNA and vigilant pneumonitis risk.
Frontline HER2-positive gastric cancer trials test T-DXd combos and TIGIT/PD-L1 bispecifics, aiming to improve survival beyond trastuzumab.
Advertisement
Advertisement
Trending on OncLive
1
Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC
2
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap
3
Docirbrutinib Yields High Response Rates in MCL and CLL
4
Signatera Is Submitted to Japan's PMDA for Companion Diagnostic Approval in MIBC
5